All In Biotech

Drug Trial Radar · NCT01513239

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II)

Last checked: Nov 19, 2026Latest source record: Sep 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,203 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,203

Actual

Start

Feb 1, 2012

Primary completion

May 22, 2015

Study completion May 22, 2015

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MK-3415A is the combination of monoclonal antibodies to Clostridium (C.) difficile toxin A (MK-3415) and toxin B (MK-6072). This study will investigate whether: 1) treatment with MK-6072 or MK-3415A in addition to standard of care (SOC) antibiotic therapy will decrease Clostridium Difficile Infection (CDI) recurrence compared with placebo; and 2) MK-6072 and MK-3415A will be generally well tolerated in participants receiving SOC therapy for CDI compared with placebo.

Conditions

  • Clostridium Difficile Infection

Interventions

  • MK-6072Biological

    Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)

  • MK-3415ABiological

    Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)

  • PlaceboBiological

    Single IV infusion of normal saline (0.9% sodium chloride)

  • SOCDrug

    SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With CDI RecurrenceTime frame: 12 weeks
  2. Percentage of Participants With One or More Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
  3. Percentage of Participants With One or More Drug-related Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
  4. Percentage of Participants With One or More Serious Drug-related Adverse Events During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
  5. Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event During 4 Weeks Following Infusion TreatmentTime frame: Up to 4 weeks
  6. Percentage of Participants With One or More Infusion-specific Adverse Events on the Day of Infusion or the Day After InfusionTime frame: Up to 24 hours

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.